BACKGROUND Cabazitaxel, abiraterone, and enzalutamide are survival-prolonging treatments in men with castration-resistant prostate cancer (CRPC) progressing following docetaxel chemotherapy. The sequential activity of these agents has not been studied and treatment sequencing remains a key dilemma for clinicians. OBJECTIVE To describe the antitumour activity of cabazitaxel after docetaxel and...

Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-negative PC-3 cells was assessed by cellular and molecular analyses. The present study demonstrated, that abiraterone treatment significantly...

As with many other biological systems, cancer is highly complex and dynamic. It now well acknowledged that the biology of tumors, including prostate cancer, evolves over time displays a huge level spatial temporal heterogeneity, at least in metastatic setting. Although prognosis patients has improved considerably introduction next-generation androgen receptor (AR)-targeted therapy, chemotherapy...